Access cutting-edge hematopoietic stem cell transplantation treatment through this clinical trial at a research site in Bethesda. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Bethesda location
Preparing your pre-screening questions…
Access hematopoietic stem cell transplantation specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hematopoietic stem cell transplantation treatment provided free
Check if you qualify for this hematopoietic stem cell transplantation clinical trial in Bethesda, MD
No-Cost Study Care
Local to Bethesda
Convenient for MD residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Infections are a major cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplant (HSCT). The purpose of this study is to evaluate if metagenomic next-generation sequencing (mNGS) can detect microbial signatures in people undergoing HSCT, and if microbial identification can be correlated with clinical features of infection (e.g., fever). Participants undergoing HSCT as part of other studies at the NIH Clinical Center (CC) will provide blood before the transplant and through 6 months after. Total nucleic acid will be extracted from plasma and subjected to mNGS. The primary objective of this study is to investigate if by using plasma and an mNGS approach, we can detect bacterial, fungal, protozoan, or viral DNA/RNA over time, in immunocompromised patients undergoing transplantation. Secondary objectives are to: (1) To correlate microbial identification with episodes of fever or clinical suspicion of infection; and to (2) correlate change in microbial signatures in patients with suspected immune reconstitution inflammatory syndrome. The study is conducted at the NIH Clinical Center. Participants, aged 3 years and older, on other research studies at the NIH CC who are undergoing HSCT are invited to take part of this study. Expected participation is up to six months.
Sponsor: National Institutes of Health Clinical Center (CC)
Yes, this clinical trial (NCT06904053) has an active research site in Bethesda, MD that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hematopoietic stem cell transplantation treatment options in Bethesda, MD, this clinical trial (NCT06904053) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Bethesda research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hematopoietic stem cell transplantation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hematopoietic stem cell transplantation clinical trials near you to find additional studies recruiting in your area.
See all essential tremor clinical trials recruiting in Bethesda — not just this study.
Browse Essential Tremor Trials in Bethesda →